Role of DNA methylation in cancer development and its clinical applications

Abstract

methyltransferase gene (DNA) methylation is a key process in epigenetic modification. This transformation leads to genomic instability that creates an impact on gene expression. DNA methylation is also involved in several mutations of tumour suppressor genes (TSGs) or proto-oncogenes, resulting in cancer (hypermethylation and hypomethylation). Hypermethylation of promoter segments in TSGs causes transcriptional silencing, whereas hypomethylation of regulatory sequence activates proto-oncogenes and retrotransposons. DNA methylation regulated by DNA methyltransferases is one of the essential epigenetic mechanisms that controls the cell cycle, cell proliferation, differentiation, apoptosis and transformation in eukaryotes, leading to genetic instability of tumour cells. Recent scientific research has highlighted that DNA methylation is a vital cancer biomarker source of several parts of body fluids that allow primary-stage cancer cell detection during clinical screening. Nowadays, epigenetic biomarkers have been introduced as a decision maker with the potential to improve cancer prognosis. DNA methylation profiling helps to determine cancer at the deep genetic level, and create high impactful cancer screening approach in the future.

Keywords

cancer / cancer biomarker / DNA methylation / epigenetics

References

[1] LiL, LiC, MaoH, et al. Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. Sci Rep. 2016;6:26591.

[2] ReisAH, VargasFR, LemosB. Biomarkers of genome instability and cancer epigenetics. Tumour Biol. 2016;37(10):13029-13038.

[3] DengD, LiuZ, DuY. Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomarkers. Adv Genet. 2010;71:125-176.

[4] KlutsteinM, NejmanD, GreenfieldR, Cedar H. DNA methylation in cancer and aging. Cancer Res. 2016;76(12):3446-3450.

[5] CraigJM, Bickmore WA. The distribution of CpG islands in mammalian chromosomes. Nat Genet. 1994;7(3):376-382.

[6] KawanoH, SaekiH, KitaoH, et al. Chromosomal instability associated with global DNA hypomethylation is associated with the initiation and progression of esophageal squamous cell carcinoma. Ann Surg Oncol. 2014;21(suppl 4):S696-S6702.

[7] PanY, LiuG, ZhouF, et al. DNA methylation profiles in cancer diagnosis and therapeutics. Clin Exp Med. 2018;18(1):1-14.

[8] LuczakMW, Jagodziński PP. The role of DNA methylation in cancer development. Folia Histochem Cytobiol. 2006;44(3):143-154.

[9] ChengY, HeC, WangM, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4:62.

[10] SzyfM, Pakneshan P, RabbaniSA. DNA methylation and breast cancer. Biochem Pharmacol. 2004;68(6):1187-1197.

[11] SenoltL, Grigorian M, LukanidinE, et al. S100A4 (Mts1): is there any relation to the pathogenesis of rheumatoid arthritis? Autoimmun Rev. 2006;5(2):129-131.

[12] BirchmeierW, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta. 1994;1198(1):11-26.

[13] Mulero-NavarroS, Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol. 2008;68(1):1-11.

[14] ChowdhuryB, ChoIH, IrudayarajJ. Technical advances in global DNA methylation analysis in human cancers. J Biol Eng. 2017;11:10.

[15] ZhangY, Jeltsch A. The application of next generation sequencing in DNA methylation analysis. Genes. 2010;1(1):85-101.

[16] McCabeMT, Brandes JC, VertinoPM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res. 2009;15(12):3927-3937.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.